NAD Supplementation for Cognitive Decline and Dementia

Introduction to NAD Supplementation Guidelines

• The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend against systematic nutrient supplementation for dementia when no deficiency exists, as current evidence does not support routine NAD+ or NAD+ precursor supplementation for preventing or treating dementia and cognitive decline in clinical practice 1, 2

Guideline-Based Recommendations

• The ESPEN guidelines provide a foundational framework for this recommendation, stating that nutrient supplements are unlikely to be effective in treating dementia, and systematic supplementation is not recommended for preventing or correcting cognitive decline in persons with dementia 1, 2
• The guidelines suggest that when specific nutrient deficiencies exist, those nutrients should be supplemented in normal doses, not mega-doses, to address deficiencies from malabsorption, metabolic disorders, or unbalanced diets 1, 2
• Each patient with dementia should be evaluated for possible nutrient deficiencies, but when no deficiency exists, specific supplementation is not reasonable 2

Clinical Decision Making

• Patients with dementia or cognitive decline should be screened for specific nutrient deficiencies, particularly B vitamins, given their role as cofactors in metabolic processes, and if deficiencies are identified, supplement those specific nutrients in normal doses 1, 2
• The ESPEN guidelines specifically address omega-3 fatty acids, B vitamins, vitamin E, selenium, copper, and vitamin D, all showing no benefit for cognitive decline in dementia when no deficiency exists 1, 3, 4, 5, 6

Future Research Directions

• If future high-quality RCTs demonstrate benefit, potential candidates for NAD supplementation might include patients with documented NAD+ deficiency states or specific populations experiencing cognitive stress or metabolic impairment affecting NAD+ metabolism 3, 6